Drug Trial Radar · NCT06667700
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,082
Planned (sponsor's estimate)
Start
Dec 2, 2024
Primary completion
Jan 26, 2031
Study completion Jan 26, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect. Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.
Conditions
- Coronavirus Disease (COVID-19)
Interventions
MolnupiravirDrug
Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
PlaceboDrug
Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced One or More of Following Through Day 29: All-cause Hospitalization, All-cause Mortality, or Covid-19-related Medically-attended Visit (MAV)Time frame: Up to 29 days
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 5 months
- Percentage of Participants Who Discontinued Study Intervention Due to AETime frame: Up to approximately 5 days
Locations
230 sites in 24 countries. Site status is shown where the registry gives one.
Cullman Clinical Trials ( Site 3813)
Cullman, Alabama · Completed
Helios Clinical Research ( Site 3826)
Paradise Valley, Arizona · Recruiting
Absolute Clinical Research ( Site 3709)
Phoenix, Arizona · Completed
Clinica de Salud del Valle de Salinas ( Site 3825)
Castroville, California · Recruiting
Ascada Health PC dba Ascada Research ( Site 3750)
Fullerton, California · Completed
Pacific Clinical Studies ( Site 3827)
Los Alamitos, California · Recruiting
Valley Clinical Trials, Inc. ( Site 3707)
Northridge, California · Recruiting
FOMAT Medical Research ( Site 3720)
Oxnard, California · Recruiting
Paradigm Clinical Research, LLC ( Site 3785)
San Diego, California · Recruiting
Optimus Medical ( Site 3817)
San Francisco, California · Recruiting
Millennium Clinical Trials ( Site 3758)
Westlake Village, California · Recruiting
Paradigm Clinical Research Centers, Inc ( Site 3718)
Wheat Ridge, Colorado · Recruiting
Encore Medical Research of Boynton Beach ( Site 3701)
Boynton Beach, Florida · Recruiting
Prestige Clinical Research Center ( Site 3722)
Coral Gables, Florida · Recruiting
Prestige Clinical Research ( Site 3830)
Homestead, Florida · Recruiting
Accel Research Sites Network - St. Pete-Largo Clinical Research Unit ( Site 3779)
Largo, Florida · Recruiting
Clinical Site Partners, LLC dba Flourish Research ( Site 3717)
Leesburg, Florida · Recruiting
Advanced Pulmonary Research Institute ( Site 3781)
Loxahatchee Groves, Florida · Active not recruiting
Southern Clinical Research ( Site 3773)
Miami, Florida · Recruiting
Florida Pharmaceutical Research and Associates ( Site 3763)
Miami, Florida · Recruiting
Bio-Medical Research LLC ( Site 3804)
Miami, Florida · Recruiting
Bright Research Center ( Site 3746)
Miami, Florida · Completed
Miami Clinical Research ( Site 3729)
Miami, Florida · Recruiting
Reed Medical Research ( Site 3761)
Miami, Florida · Recruiting
Palm Springs Community Health Center ( Site 3757)
Miami Lakes, Florida · Recruiting
Panax Clinical Research ( Site 3803)
Miami Lakes, Florida · Recruiting
Indago Research and Health Center Inc ( Site 3714)
Miami Lakes, Florida · Recruiting
Combined Research Orlando Phase I-IV ( Site 3797)
Orlando, Florida · Recruiting
CDC Research Institute ( Site 3716)
Port Saint Lucie, Florida · Recruiting
New Tampa Health ( Site 3764)
Tampa, Florida · Recruiting
Clinical Research Trials of Florida ( Site 3703)
Tampa, Florida · Recruiting
Precision Research Center ( Site 3704)
Tampa, Florida · Recruiting
Encore Medical Research - Weston ( Site 3708)
Weston, Florida · Completed
Balanced Life Health Care Solutions/SKYCRNG ( Site 3713)
Lawrenceville, Georgia · Completed
Renew Health Clinical Research ( Site 3760)
Snellville, Georgia · Recruiting
Rophe Adult and Pediatric Medicine/SKYCRNG ( Site 3816)
Union City, Georgia · Completed
Paradigm Clinical Research - Boise ( Site 3841)
Boise, Idaho · Completed
Rush University Medical Center ( Site 3748)
Chicago, Illinois · Recruiting
Duly Health and Care ( Site 3799)
Lombard, Illinois · Recruiting
University of Louisville School of Medicine ( Site 3706)
Louisville, Kentucky · Recruiting
Showing 40 of 230 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.